首页> 外文期刊>American Journal of Nursing: Official Magazine of the American Nurses' Associstion >Perioperative medication withholding in patients disease: A retrospective electronic health records review
【24h】

Perioperative medication withholding in patients disease: A retrospective electronic health records review

机译:病人疾病的围手术期用药禁忌:回顾性电子病历回顾

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Carbidopa-levodopa (Sinemet), the gold-standard treatment for Parkinson's disease, has a short half-life of one to two hours. When patients with Parkinson's disease are placed on npo (nil per os, or nothing by mouth) status for surgery, they may miss several doses of carbidopa-levodopa, possibly result-ing in exacerbation of Parkinson's disease symptoms. Clear guidelines regarding perioperative symptom management are lacking. Objectives: The goals of this study were threefold: to measure the perioperative duration of the with-holding of carbidopa-levodopa in patients with Parkinson's disease, to record the time of day surgeries were performed on these patients, and to record perioperative exacerbations of Parkinson's disease symp- toms. Methods: We conducted a retrospective review of patient electronic health records at a Midwestern public medical center. After applying inclusion and exclusion criteria and evaluating the eligible records, we had a final sample of 89 separate surgical events for 67 discrete patients who had been diagnosed with Parkinson's disease, had undergone any type of surgery excepting Parkinson's disease surgeries, and were taking carbidopa-levodopa. Results: The median duration of carbidopa-levodopa withholding was 12.35 hours, with most surgi-cal procedures (86%) starting at 9 am or later. The most commonly reported exacerbation of Parkinson's disease symptoms was agitation or confusion. Conclusions: For best symptom management, careful consideration should be given to scheduling sur-gery at the earliest possible time, administering medications as close to the patient's usual dosing sched-ule as possible, and providing nursing education about optimal medication management for this patient population.
机译:背景:卡比多巴-左旋多巴(Sinemet)是帕金森氏病的金标准疗法,半衰期只有一到两个小时。当帕金森氏病患者处于非手术状态(每口无口服,或经口无口服)时,他们可能会错过几剂卡比多巴-左旋多巴,可能导致帕金森氏病症状加重。缺乏有关围手术期症状管理的明确指南。目的:本研究的目标是三个方面:测量帕金森氏病患者卡比多巴-左旋多巴停药的围手术期,记录这些患者的手术时间,并记录帕金森病的围手术期加重情况。疾病症状。方法:我们在中西部公共医疗中心对患者的电子健康记录进行了回顾性审查。在应用纳入和排除标准并评估合格记录后,我们对67位离散型患者的89个单独的手术事件进行了最终抽样,这些患者已被诊断出患有帕金森氏病,除了帕金森氏病手术之外还接受过其他类型的手术,并且正在服用卡比多巴左旋多巴。结果:停用卡比多巴-左旋多巴的中位时间为12.35小时,大多数手术操作(86%)从上午9点或更晚开始。最常报告的帕金森氏病症状加重是躁动或神志不清。结论:为获得最佳症状管理,应谨慎考虑尽早进行急诊手术,尽可能接近患者的常规给药时间表进行药物治疗,并为该患者群体提供最佳药物管理的护理教育。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号